The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 23, Issue 6, 2017, Pages 1493-1505

  Matas Céspedes, Alba ^a   Vidal Crespo, Anna ^a   Rodriguez, Vanina ^a   Villamor, Neus ^a,b   Delgado, Julio ^b   Giné, Eva ^b   Roca Ho, Heleia ^c   Menéndez, Pablo ^c,d   Campo, Elías ^b   López Guillermo, Armando ^b   Colomer, Dolors ^a,b   Roué, Gaël ^a   Wiestner, Adrian ^e   Parren, Paul W H I ^f,g,h   Doshi, Parul ⁱ   Van Bueren, Jeroen Lammerts ^f   Pérez Galán, Patricia ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f GENMAB   (Netherlands)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ Janssen R and D   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARATUMUMAB; GELATINASE B; VASCULAR CELL ADHESION MOLECULE 1; ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELL PHAGOCYTOSIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL ADHESION; CELL HOMING; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHAGOCYTOSIS; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; CELL PHAGOCYTOSIS; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ADP-RIBOSYL CYCLASE 1; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CYTOPHAGOCYTOSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MATRIX METALLOPROTEINASE 9; MICE; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016153596     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2095     Document Type: Article

References (48)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: World Health Organization (WHO) Press-International Agency for Research on Cancer (IARC). 4th ed. 2008.
3. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-64.
4. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94: 1840-7.
5. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-9.
6. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008;111:5173-81.
7. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-74.
8. Jaksic O, Paro MM, Kardum Skelin I, Kusec R, Pejsa V, Jaksic B. CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. Blood 2004;103:1968-9.
9. Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007; 110:3352-9.
10. Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, Bonello L, et al. CD38 and ZAP-70 are functionally linked andmark CLL cells with high migratory potential. Blood 2007;110:4012-21.
11. Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G, et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010;24:958-69.
12. Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003;102:2146-55.
13. Buggins AG, Levi A, Gohil S, Fishlock K, Patten PE, Calle Y, et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 2011;154: 216-22.
14. Vaisitti T, Serra S, Pepper C, Rossi D, Laurenti L, Gaidano G, et al. CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells. Leukemia 2013;27:1177-81.
15. Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D, et al. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia 2012; 26:1301-12.
16. Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nuckel H, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 2014;32: 897-904.
17. Laubach JP, Richardson PG. CD38-targeted immunochemotherapy in refractory multiple myeloma: a new horizon. Clin Cancer Res 2015; 21:2660-2.
18. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, HanssonM, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373:1207-19.
19. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551-60.
20. de Weers M., Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840-8.
21. Overdijk MB, Verploegen S, Bogels M, van EM, van Bueren JJ, Mutis T, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 2015;7:311-21.
22. Overdijk MB, Jansen JH, NederendM, Lammerts van Bueren JJ, Groen RW, Parren PW, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fcgamma receptor-mediated cross-linking. J Immunol 2016;197:807-13.
23. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 2016; 128:384-94.
24. Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, Zito A, et al. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology 2013;2:e26246.
25. Lammerts van Bueren J, Jakobs D, Kaldenhovenm N, Roza M, Hiddinghm S, Meesters J, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood 2014;124:3474.
26. Endell J, Boxhammer R, Wurzenberger C, Ness D, Steidl S. The activity of MOR202, a fully human anti-CD38 antibody, is complemented by ADCP and is synergistically enhanced by lenalidomide in vitro and in vivo. ASH Annual Meeting Abstracts 2012;120:4018.
27. Deckert J, WetzelMC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallee F, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 2014; 20:4574-83.
28. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-7.
29. Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29:329-36.
30. van der Veers MS, deWeersM., van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011;96:284-90.
31. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999;94: 3658-67.
32. Loisel S, Ster KL, Quintin-Roue I, Pers JO, Bordron A, Youinou P, et al. Establishment of a novel human B-CLL-like xenograft model in nude mouse. Leuk Res 2005;29:1347-52.
33. Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson PG. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase I/II study. ASH Annual Meeting Abstracts 2012;120:73.
34. Bertilaccio MT, Scielzo C, Simonetti G, Ponzoni M, Apollonio B, Fazi C, et al. A novel Rag2-/-gammac-/-xenograft model of human CLL. Blood 2010;115:1605-9.
35. Klein C, Bacac M, Umana P, Wenger M. Obinutuzumab (Gazyva), a novel glycoengineered type II CD20 antibody for the treatment of chronic lymphocytic leukemia and non-hodgkin's lymphoma. In:Dübel, SReichert JM, editors. Handbook of therapeutic antibodies. Weinberg, Germany: Wiley-VCH Verlag GmbH & Co; 2014. p.1695-732.
36. Lindorfer MA, Bakker JM, Parren P.W.H.I., Taylor RP. Ofatumumab: a nextgeneration human therapeutic CD20 antibody with potent complementdependent cytotoxicity. In: Dübel S,Reichert JM, editors. Handbook of therapeutic antibodies. Weinberg, Germany: Wiley-VCH Verlag GmbH & Co; 2014. p.1733-74.
37. Nijhof IS, Groen RW, Lokhorst HM, van KB, Bloem AC, van VJ, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia 2015;29: 2039-49.
38. Nijhof IS, Groen RW, Noort WA, van KB, de Jong-Korlaar R, Bakker J, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res 2015;21:2802-10.
39. Teeling JL, French RR, Cragg MS, van den BJ, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104: 1793-800.
40. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40:109-23.
41. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 2013;132:536-44.
42. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cellmediated cytolysis. Annu Rev Immunol 2001;19:197-223.
43. Nijhof IS, Lammerts van Bueren JJ, van KB, Andre P, Morel Y, Lokhorst HM, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica 2015;100:263-8.
44. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013;496:445-55.
45. Schwartz JB, Shamsuddin AM. The effects of leukemic infiltrates in various organs in chronic lymphocytic leukemia. Hum Pathol 1981;12:432-40.
46. Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, et al. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia 2013;27:2311-21.
47. Redondo-Munoz J, Escobar-Diaz E, Samaniego R, Terol MJ, Garcia-Marco JA, Garcia-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is upregulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006;108:3143-51.
48. Kamiguti AS, Lee ES, Till KJ, Harris RJ, Glenn MA, Lin K, et al. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol 2004;125:128-40.